0.7334
price down icon5.43%   -0.0421
pre-market  Pre-mercato:  .73   -0.0034   -0.46%
loading
Precedente Chiudi:
$0.7755
Aprire:
$0.7628
Volume 24 ore:
1.71M
Relative Volume:
0.17
Capitalizzazione di mercato:
$71.86M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-9.70%
1M Prestazione:
-2.63%
6M Prestazione:
-85.90%
1 anno Prestazione:
-76.03%
Intervallo 1D:
Value
$0.726
$0.7876
Intervallo di 1 settimana:
Value
$0.726
$0.83
Portata 52W:
Value
$0.64
$7.2904

Atyr Pharma Inc Stock (ATYR) Company Profile

Name
Nome
Atyr Pharma Inc
Name
Telefono
(858) 731-8389
Name
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Name
Dipendente
59
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
ATYR's Discussions on Twitter

Confronta ATYR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ATYR
Atyr Pharma Inc
0.7334 75.99M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.71 114.69B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
752.62 77.91B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
850.95 54.05B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
391.50 52.52B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
196.92 42.02B 447.02M -1.18B -906.14M -6.1812

Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-09-16 Downgrade RBC Capital Mkts Outperform → Sector Perform
2025-09-15 Downgrade Cantor Fitzgerald Overweight → Neutral
2025-09-15 Downgrade H.C. Wainwright Buy → Neutral
2025-09-15 Downgrade Leerink Partners Outperform → Market Perform
2025-09-15 Downgrade Wells Fargo Overweight → Equal Weight
2025-02-18 Iniziato Leerink Partners Outperform
2025-01-06 Iniziato Cantor Fitzgerald Overweight
2024-10-04 Iniziato Wells Fargo Overweight
2024-09-05 Iniziato Jefferies Buy
2023-07-05 Downgrade Oppenheimer Outperform → Perform
2021-10-12 Iniziato RBC Capital Mkts Outperform
2021-09-21 Iniziato Piper Sandler Overweight
2021-05-10 Iniziato Laidlaw Buy
2020-08-17 Aggiornamento H.C. Wainwright Neutral → Buy
2020-03-04 Iniziato ROTH Capital Buy
2020-03-02 Iniziato Oppenheimer Outperform
2018-02-14 Downgrade JP Morgan Neutral → Underweight
2017-09-07 Iniziato Piper Jaffray Overweight
2016-12-13 Downgrade JP Morgan Overweight → Neutral
2015-12-16 Iniziato Citigroup Neutral
2015-06-01 Iniziato Citigroup Buy
2015-06-01 Iniziato JP Morgan Overweight
Mostra tutto

Atyr Pharma Inc Borsa (ATYR) Ultime notizie

pulisher
Dec 15, 2025

Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders - marketscreener.com

Dec 15, 2025
pulisher
Dec 15, 2025

aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Dec 15, 2025
pulisher
Dec 15, 2025

aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of “Hold” by Brokerages - Defense World

Dec 15, 2025
pulisher
Dec 09, 2025

Healthy Upside Potential: Atyr Pharma Inc (ATYR) - Setenews

Dec 09, 2025
pulisher
Dec 08, 2025

ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit - Morningstar

Dec 08, 2025
pulisher
Dec 08, 2025

Investors SueWallSt Over aTyr Pharma, Inc. Stock DropContact Levi & Korsinsky to Join - Louisiana First News

Dec 08, 2025
pulisher
Dec 08, 2025

Shareholders that lost money on aTyr Pharma, Inc.(ATYR) - GlobeNewswire

Dec 08, 2025
pulisher
Dec 08, 2025

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - galvnews.com

Dec 08, 2025
pulisher
Dec 08, 2025

ATYR DEADLINE ALERT: Hagens Berman Alerts aTyr Pharma - GlobeNewswire

Dec 08, 2025
pulisher
Dec 08, 2025

ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc - GuruFocus

Dec 08, 2025
pulisher
Dec 08, 2025

ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire

Dec 08, 2025
pulisher
Dec 08, 2025

ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com

Dec 08, 2025
pulisher
Dec 08, 2025

ATyr Pharma, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsATYR - marketscreener.com

Dec 08, 2025
pulisher
Dec 07, 2025

ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - TMX Newsfile

Dec 07, 2025
pulisher
Dec 06, 2025

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - GlobeNewswire

Dec 06, 2025
pulisher
Dec 06, 2025

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - GlobeNewswire Inc.

Dec 06, 2025
pulisher
Dec 06, 2025

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Newsfile

Dec 06, 2025
pulisher
Dec 05, 2025

מועד אחרון לתביעה נגד ATYR: רוזן, משרד עורכי דין מוערך בעולם, מעודדים את משקיעי ATyr Pharma, Inc עם הפסדים של מעל מאה אלף דולר, להשיג ייעוץ לפני המועד החשוב של 8 בדצמבר בתביעה ייצוגית בניירות ערך - GlobeNewswire Inc.

Dec 05, 2025
pulisher
Dec 05, 2025

ATYR DEADLINE MONDAY: ROSEN, A GLOBALLY RESPECTED LAW FIRM, - GlobeNewswire

Dec 05, 2025
pulisher
Dec 05, 2025

aTyr Pharma Receives Nasdaq Deficiency Notice - TipRanks

Dec 05, 2025
pulisher
Dec 05, 2025

Investors who lost money on aTyr Pharma, Inc.(ATYR) should contact Levi & Korsinsky about pending Class ActionATYR - Your Wyoming Link

Dec 05, 2025
pulisher
Dec 05, 2025

ATyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - marketscreener.com

Dec 05, 2025
pulisher
Dec 05, 2025

ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Dec 05, 2025
pulisher
Dec 05, 2025

SueWallSt Podcast Series Launches With Focus on aTyr Pharma, Inc. (ATYR) Fraud Allegations - ACCESS Newswire

Dec 05, 2025
pulisher
Dec 05, 2025

ATYR 3-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Inves - GuruFocus

Dec 05, 2025
pulisher
Dec 05, 2025

ATYR 3-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - marketscreener.com

Dec 05, 2025
pulisher
Dec 05, 2025

Holzer & Holzer, LLC Reminds Investors of Upcoming December - GlobeNewswire

Dec 05, 2025
pulisher
Dec 04, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire

Dec 04, 2025
pulisher
Dec 04, 2025

Deadline Soon: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal

Dec 04, 2025
pulisher
Dec 04, 2025

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - WV News

Dec 04, 2025
pulisher
Dec 04, 2025

aTyr Pharma, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before December 8, 2025 to Discuss Your RightsATYR - PR Newswire

Dec 04, 2025
pulisher
Dec 04, 2025

aTyr Pharma, Inc. $ATYR Shares Bought by Geode Capital Management LLC - Defense World

Dec 04, 2025
pulisher
Dec 03, 2025

ATYR 5-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Inves - GuruFocus

Dec 03, 2025
pulisher
Dec 03, 2025

ATYR 5-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - Morningstar

Dec 03, 2025
pulisher
Dec 03, 2025

Shareholders SueWallSt in New Class Action Against aTyr Pharma, Inc.Act Now - Nasdaq

Dec 03, 2025
pulisher
Dec 03, 2025

ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - GlobeNewswire

Dec 03, 2025
pulisher
Dec 02, 2025

Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - MarketScreener

Dec 02, 2025
pulisher
Dec 02, 2025

ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire

Dec 02, 2025
pulisher
Dec 02, 2025

Deadline Alert: aTyr Pharma Inc. (ATYR) Shareholders Who - GlobeNewswire

Dec 02, 2025
pulisher
Dec 02, 2025

Shareholders that lost money on aTyr Pharma, Inc.(ATYR) should c - GuruFocus

Dec 02, 2025
pulisher
Dec 02, 2025

Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors - GlobeNewswire

Dec 02, 2025
pulisher
Dec 02, 2025

The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineATYR - Lelezard

Dec 02, 2025
pulisher
Dec 02, 2025

Will aTyr Pharma Inc. (471A) stock profit from fiscal stimulusQuarterly Risk Review & Low Volatility Stock Recommendations - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

How aTyr Pharma Inc. (471A) stock valuation compares with sectorMarket Trend Review & Consistent Profit Trading Strategies - Newser

Dec 02, 2025
pulisher
Dec 01, 2025

ATYR 1-WEEK DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - Morningstar

Dec 01, 2025
pulisher
Dec 01, 2025

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - marketscreener.com

Dec 01, 2025
pulisher
Dec 01, 2025

Bragar Eagel & Squire, P.C. Urgently Reminds Stockholders - GlobeNewswire

Dec 01, 2025
pulisher
Dec 01, 2025

Lost Money on aTyr Pharma, Inc.(ATYR)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire

Dec 01, 2025
pulisher
Dec 01, 2025

aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com

Dec 01, 2025

Atyr Pharma Inc Azioni (ATYR) Dati Finanziari

Non sono disponibili dati finanziari per Atyr Pharma Inc (ATYR). Controlla altri titoli per ulteriori informazioni.

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Atyr Pharma Inc Azioni (ATYR) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
SCHIMMEL PAUL
Director
Oct 09 '25
Buy
0.94
317,999
299,364
1,413,023
Gross Jane A
Director
Mar 17 '25
Buy
4.00
3,750
15,000
9,750
Broadfoot Jill Marie
Chief Financial Officer
Feb 04 '25
Sale
3.78
1,254
4,740
31,763
DENYES NANCY
General Counsel
Feb 04 '25
Sale
3.78
899
3,398
26,555
$38.53
price up icon 0.36%
$98.64
price up icon 3.39%
$31.57
price up icon 0.83%
$93.81
price down icon 1.05%
biotechnology ONC
$310.67
price down icon 2.63%
$196.92
price down icon 0.05%
Capitalizzazione:     |  Volume (24 ore):